Biogen completes acquisition of RayThera
Reuters2026/08/06 22:33- Biogen completed its acquisition of privately held RayThera, adding small-molecule immunology programs to its pipeline.
- The deal expands Biogen’s immunology portfolio with multiple assets targeting immune-mediated conditions across several indications.
- RayThera’s lead program entered Phase 1 development in July 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Today's Fear & Greed Index rises to 65, indicating the market is in a 'greed' state.
CFTC files motion to dismiss CME's motion regarding perpetual contracts lawsuit
At a sensitive moment of the "bond market storm," the market focuses on today's 30-year Japanese government bond auction.
Japan’s 30-year government bond yield has risen to 4.155%, approaching a historic high. The 30-year bond auction scheduled for Thursday is drawing significant attention. Analysts generally expect a weak result and warn that if the auction goes poorly, it could put reverse pressure on US Treasuries, prompting a repricing of the global fixed income market and potentially becoming a new trigger for rising global borrowing costs.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
